A B S T R A C T The first step in the degradation of the steroid side chain during biosynthesis of bile acids from cholesterol in man was studied in microsomal and mitochondrial fraction of homogenate of livers from 14 patients.
INTRODUCTION
According to current concepts of the biosynthesis of bile acids from cholesterol in mammalian liver, the changes Receivcd for publication 17 September 1974 and in revised form 4 November 1974. in the steroid nucleus precede the degradation of the steroid side chain (1) , and 5j3-cholestane-3a,7a,12a-triol and 5P-cholestane-3a,7a-diol have been postulated as intermediates in the biosynthesis of cholic acid1 and chenodeoxycholic acid,' respectively. The sequence of reactions leading to the formation of 5,8-cholestane-3a,7a-diol in rat liver (1) , guinea pig liver (2) , as well as human liver (3) appears to be the following: cholesterol -> 5-cholestene-3fi,7a-diol --7a-hydroxy-4-cholesten-3-one -> 7a-hydroxy-5P-cholestan-3-one > 5P-cholestane3a,7a-diol. In the sequence of reactions leading to 59-cholestane-3a,7a,12a-triol, a 12a-hydroxyl group is introduced, probably at the stage of 7a-hydroxy-4-cholesten- 3-one (1) . The mechanisms of degradation of the side chains in 5,8-cholestane-3a,7a-diol and 53-cholestane-3a,-7a,12a-triol have not been completely established. Studies in vitro with preparations from rat liver show that in the major pathway for the degradation of the side chain, microsomal and/or mitochondrial 26-hydroxylation is the initial reaction (1, (4) (5) (6) (7) . The possibility that side chain degradation starts with a 25-hydroxylation has also been discussed, but there is little experimental evidence as yet to support this pathway.
No studies in vitro on the degradation of the steroid side chain have been performed with human liver. There are indications that one mechanism of side chain degradation in man involves 26-hydroxylation. 3a,7a-Dihydroxy-5,0-cholestanoic acid and 3a,7a,12a-trihydroxy-513-cholestanoic acid have been 16.7 ,uCi/mg) were prepared as described previously (5) . cholestane-3a,7a,12a,26-tetrol, and 5,B-cholestane-3a,7a,12a, 24-tetrol were prepared as described previously (4, 5). 5,BCholestane-3a,7a,12a,24-tetrol was a mixture of the 24a-and 24jB-epimers (4 20 ,000 g, and 100,000 g (5). The microsomal pellet was resuspended in the homogenizing medium and homogenized before incubation. In a few experiments the final resuspension was made in a modified Bucher medium (2) . The mitochondrial fraction was obtained by resuspension in 0.25 M sucrose of the pellet obtained after centrifugation at 20,000 g and recentrifugation at 8,500 g for 12 min. The precipitate obtained was resuspended in 0.1 M Tris-Cl buffer, pH 7.4. The microsomal and the mitochondrial fractions were resuspended in the final step to a volume corresponding to that of the original 800 g supernate from which they had been prepared. The protein content of the microsomal fraction and the mitochondrial fraction was between 2.7 and 4.4 mg/ml and between 1.1 and 3.3 mg/ml, respectively, when determined according to the Lowry, Rosebrough, Farr, and Randall procedure (14) . The cholesterol content of the mitochondrial fraction was about 1.0 mg/100 ml as determined by gas chromatography of the trimethylsilyl ether.
Incubation procedures and analysis of incubation mixtures. In standard incubations with the microsomal fractions, 250
,gg of the steroid, dissolved in 50 ,gl of acetone, was incubated with 1.5 ml of the microsomal fraction in a total volume of 3 ml of the homogenizing medium (5). An isocitrate-dependent NADPH-generating system was used, containing 3 ,gmol of NADP (5) . In standard incubations with the mitochondrial fraction, 100 jug of the steroid dissolved in 50 gul of acetone was incubated with 1.0 ml of the mitochondrial fraction in a total volume of 3 ml of the homogenizing medium (5) . In these incubations, only isocitrate, 4.6 ,Amol, was used as cofactor. In some cases (Table IV) and subjected to thin-layer chromatography as described previously (5) . Ethyl acetate was the solvent in the incubations with 5,6-cholestane-3a,7a-diol and 5-cholestene-3,8,7a-diol; benzene-ethyl acetate (1:4, vol/vol) in the incubations with 7a-hydroxy-4-cholesten-3-one; benzene-ethyl acetate (1:1, vol/vol) in the incubations with cholesterol; system S7 (15) in the case of incubations with 5,3-cholestane-3a,7a, 12a-triol. In most cases, the corresponding unlabeled 26-hydroxylated derivatives were added as external standards. Radioactivity in the different chromatographic zones was assayed with a thin-layer scanner (Berthold, Karlsruhe, W. Germany) and it was ascertained that this method of assay gave the same results as the method used earlier to assay extent of conversion (cf. refs. 2-7), i.e. elution of appropriate zones from the thin-layer chromatograms and determination of radioactivity in the methanol extracts by liquid scintillation counting. The chromatographic zones corresponding to the 26-hydroxylated products were extracted with methanol, converted into trimethylsilyl ethers (16) and subjected to radio-gas chromatography with a Barber-Colman 5000 instrument equipped with a 3% QF-1 column (Barber-Colman Company, Rockford, Ill.). When present, 23-, 24-, 25-, and 12a-hydroxylated products were found in the thinlayer chromatographic zone corresponding to the 26-hydroxylated products, and these products separated on gas chromatography (4, 5) . The conversion into the different products was calculated from the amount of radioactivity found in the thin-layer chromatographic zone and the amount of radioactivity found with the appropriate retention time in the radio-gas chromatogram. As shown previously (5), there was a linear relationship between the amount of radioactivity injected into the radio-gas chromatograph and the peak area of the radioactivity tracing. When incubations with only buffer were performed, in some cases a small amount of radioactivity (<0.2%) appeared in the zone corresponding to the 25-and 26-hydroxylated product. Radio-gas chromatography showed that these compounds were not identical with the side chain hydroxylated derivatives. In all cases, conversion of cholesterol into the 26-hydroxylated product was calculated on the assumption that the added cholesterol was equilibrated with endogenous cholesterol (, 10 jug/ml of mitochondrial fraction). Even if there were no equilibration between the added cholesterol and the endogenous cholesterol, 26-hydroxylase activity would be overestimated by less than 10%o under standard conditions (cf. ref. 7) .
In some cases, aliquots of the trimethylsilyl ethers were analyzed by combined gas chromatography-mass spectrometry with the LKB 9000 instrument equipped with a 1.5% SE-30 column (LKB-Produkter AB, Stockholm,Sweden). In the analysis of the products obtained from incubations of 5,8-cholestane-3a,7a,12a-triol with the microsomal fraction, the trimethylsilyl ether of the extract from the appropriate chromatographic zone was subjected to mass fragmentography. The mass fragmentography was performed with the above instrument equipped with a multiple ion detector. The four channels were focused on the ions in/e 131, ttn/e 145, rn/e 159, and rn/e 253, corresponding to a prominent peak or the base peak in the mass spectrum of the trimethylsilyl ether of the 25-, 24-, 23-, and 26-hydroxylated product, respectively (4).
RESULTS
Incubations with the microsomal fraction. Table II summarizes the results of incubations of the different substrates with the microsomal fraction under the standard incubation procedure with Tris-Cl as buffer. In accordance with previous work (3), 7a-hydroxy-4-cholesten-3-one and 5-cholestene-3,8,7a-diol were hydroxylated efficiently in the 12a-position. Also 5p-cholestane-3a,7a-diol was converted efficiently into the corresponding 12a-hydroxylated product, as shown by thinlayer chromatography and radio-gas chromatography of the trimethylsilyl ether. 5,-Cholestane-3a,7a,12a-triol was converted efficiently into a compound with the thin-layer chromatographic and gas-chromatographic properties of 5,8-cholestane-3a,7a,12a,25-tetrol (Figs. 1 and 2). Combined gas chromatography-mass spectrometry of the trimethylsilyl ether established the identity of the product. The mass spectrum was identical with that of the authentic compound and with previously published mass spectra (4, 13) of trimethylsilyl ether of 5,3-cholestane-3a,7a, 12a,25-tetrol. The most prominent feature in the mass spectrum of this compound is the base peak at m/e 131, corresponding to cleavage between C24 and C25. In most incubations with 5,8-cholestane-3a,-7a, 12a-triol, small amounts of products with the thinlayer chromatographic and gas-chromatographic properties of 5i-cholestane-3a,7a,12a,24-tetrol and 5p-cholestane-3a,7a,12a,23-tetrol were formed. The trimethylsilyl ethers of these compounds had mass spectra identical to those of the authentic compounds (4). The most characteristic feature of the mass spectrum of the trimethylsilyl ether of 58-cholestane-3a,7a, 12a,24-tetrol is the prominent peak at m/e 145, corresponding to cleavage between Cm and C4 (4) . The most prominent feature of the mass spectrum of the trimethylsilyl ether of 5P-cholestane-3a,7a,12a,23-tetrol is the base peak at m/e 159, corresponding to cleavage between Cm and C23 (cf. ref.
4).
No attempts were made to separate 59-cholestane-3a,-7a,12a,24a-tetrol from 5P-cholestane-3a,7a,12a,24P-tetrol (4) . 26-Hydroxylation of 5,8-cholestane-3a,7a,12a-triol could not be detected with either the radio-gas chromatographic technique (Fig. 2) or mass fragmentography (Fig. 3) . In the mass fragmentography, the specific ions at m/e 253, m/e 131, m/e 145, m/e 159 were followed through the gas chromatogram. The ion at m/e 253 is the base peak in the mass spectrum of the trimethylsilyl ether of 5P8-cholestane-3a,7a,12a,26-tetrol (4) and is prominent in mass spectra of trimethylsilyl ethers of all C27-steroids with three hydroxyl groups in the steroid nucleus (4, 17) . No significant peak with the retention time characteristic of 5,8-cholestane-3a,7a,12a,26-tetrol could be detected in the recording of the ions at m/e 253, whereas peaks could be detected in this recording with retention times characteristic of trimethylsilyl ethers of 5P-cholestane-3a,7a,12a,25-tetrol, 5p-cholestane-3a,7a,-12a,24-tetrol, and 5p-cholestane-3a,7a,12a,23-tetrol (Fig.  3) . As expected there were peaks in the recording at m/e 131, m/e 145, and m/e 159 at retention times corresponding to trimethylsilyl ether of 5,8-cholestane-3a,7a,-12a,25-tetrol, 5P-cholestane-3a,7a,12a,24-tetrol, and 5P-cholestane-3a,7a,12a,23-tetrol, respectively (Fig. 3) . In addition to the gas-chromatographic peaks corresponding to the trimethylsilyl ethers of 23-, 24-, and 25-hydroxylated 5P6-cholestane-3a,7a,12a-triols, several sharp peaks appeared in the chromatogram shown in Fig. 3 . These peaks did not correspond to compounds of steroid nature as judged from their mass spectra. (Table II) 5,8-cholestane-3a,7a,25-triol never exceeded 10% of total products.
In one incubation with 5-cholestene-3#,7a-diol with the microsomal fraction (Table II) (Table II) .
The 25-hydroxylation of 5,8-cholestane-3a,7a,12a-triol was studied in more detail with microsomal fraction obtained from one of the liver samples (patient 14). The rate of 25-hydroxylation was found to be linear with microsomal protein up to 8 mg and with time up to about 40 min (Fig. 4) . The enzyme appeared to be saturated with 250 Ag of substrate.
In the above series of experiments, Tris-Ci was used as incubation medium since with rat liver microsomes 26-hydroxylation is more efficient with this buffer than with potassium phosphate buffer (5) . In a few experiments with microsomal fraction from patients 13 and 14, a modified Bucher medium was used (2, 3) . With this medium 12a-hydroxylation and 25-hydroxylation decreased but a significant conversion of 5,8-cholestane-3a,-7a-diol and 5P-cholestane-3a,7a,12a-triol into products with the gas-chromatographic properties characteristic of the corresponding 26-hydroxylated compounds occurred. In two experiments with 5,8-cholestane-3a,7a-diol and one with 5P-cholestane-3a,7a,12a-triol, the conversion into the assumed 26-hydroxylated product was Table II) . In one experiment with 5P-cholestane-3a,7a, 12a-triol, the conversion was about 0.5 nmol/mg protein/20 min. The small amounts of product obtained in the experiments with modified Bucher medium prevented final identification by combined gas chromatography-mass spectrometry.
Incubations with the mitochondrial fraction. Table  III summarizes the results of incubations of the different substrates with the mitochondrial fraction. 26-Hy- (Fig. 5 ). Cholesterol and 5P-cholestane-3a,7a-diol were 26-hydroxylated by every mitochondrial fraction tested, whereas 5-cholestene-3P,7a-diol, 7a-hydroxy-4-cholesten-3-one, and 5f8-cholestane-3a,7a,12a-triol were 26-hydroxylated by about half of the different mitochondrial fractions tested. The mitochondrial fraction from one of the samples (patient 14) was incubated with all the different substrates (Table IV) tene-3j%,7a-diol, 5,8-cholestane-3a,7a-diol, and 59-cholestane-3a,7a,12a-triol, the final identification was performed directly with the trimethylsilyl ether of the product. The mass spectra obtained were identical to those of the authentic compounds. The characteristic features of these mass spectra have been published previously (5). In the case of incubations of 7a-hydroxy-4-cholesten-3-one, direct identification of the product by combined gas chromatography-mass spectrometry was difficult due to the long retention time on the column used. The material with the thin-layer chromatographic properties expected of 7a,26-dihydroxy-4-cholesten-3-one was therefore reduced with sodium borohydride, and the trimethylsilyl ether of the reduced product was identified by combined gas chromatography-mass spectrometry as 4-cholestene-3,8,7a,26-triol. The mass spectrum was identical to that reported previously (5 (Fig. 6) (19) .
Introduction of a 24-hydroxyl group is probably an obligatory step in the biosynthesis of bile acids, but information from experiments with rat liver preparations indicates strongly that 3a,7a,12a-trihydroxy-5p-cholestanoic acid and not 513-cholestane-3a,7a,12a-triol is the major substrate for the 24-hydroxylase system involved. in cholic acid biosynthesis (1) .
It There is evidence that all three pathways exist in rat liver. According to current concepts, a pathway involving acetone formation is of little importance, quantitatively (1, 22). 5,8-Cholestane-3a,7a,12a,25-tetrol is formed in rat liver microsomes in vitro (4), but is converted into cholic acid in vivo much less efficiently than 5,8-cholestane-3a,7a,12a,26-tetrol and 5p-cholestane-3a,-7a,12a-triol (4, 23) . The relative importance of microsomal and mitochondrial 26-hydroxylases is not clear. There is evidence to indicate that microsomal 26-hydroxylation plays a role in the regulation of the ratio of cholic acid to chenodeoxycholic acid formed from cholesterol. In the hyperthyroid rat, in which the normal cholic acid/chenodeoxycholic acid ratio is reversed, the microsomal 26-hydroxylase is increased and the 12a-hydroxylase decreased (6) . Since the presence of a 26-hydroxyl group practically prevents a subsequent 12a-hydroxylation, the observed changes in 26-and 12a-hydroxylase activities in the hyperthyroid state may explain the reversal of the ratio of cholic acid to chenodeoxycholic acid (6) .
Of the three pathways discussed, microsomal 26-hydroxylation appears to be of little importance in man, as judged from the present results. It is interesting in this connection that in contrast to the rat, the cholic acid/chenodeoxycholic acid ratio in man is affected only to a small extent by the thyroid state (24) .
The relative importance of the pathways involving mitochondrial 26-hydroxylation or microsomal 25-hydroxylation in man is difficult to assess at present. The efficient formation of 5,8-cholestane-3a,7a,12a,25-tetrol in the microsomal fraction does not necessarily indicate that a pathway involving 5,3-cholestane-3a,7a,12a,25-tetrol is important in vivo. The excretion in bile and feces of 5B-cholestane-3a,7a,12a,25-tetrol and 5,8-cholestane-3a,7a,12a,24,25-pentol by patients with cerebrotendinous xanthomatosis might have two explanations. There might be a subnormal 26-hydroxylation leading to accumulation and excretion of side products that are not intermediates in the normal pathways to bile acids. The other explanation is that the two sterols are important intermediates in the normal biosynthesis of cholic acid in man and that patients with cerebrotendinous xanthomatosis have subnormal capacity to convert these compounds into cholic acid. It was recently reported in preliminary form that patients with cerebrotendinous xanthomatosis as well as normal subjects are able to convert 5fl-cholestane-3a,7a,12a,25-tetrol into cholic acid (25) . It was concluded that the basic genetic defect in these patients was a lack of 26-hydroxylase activity and that the major part of the bile acids formed in these patients is formed through the alternate pathway involving 5,8-cholestane-3a,7a,12a,25-tetrol. As shown in the present work, the microsomal 25-hydroxylase appears to be specific for 5P-cholestane-3a,7a,12a-triol. This finding can be considered as support for the conclusion by Mosbach and Salen (25) that patients with cerebrotendinous xanthomatosis utilize pathways to cholic acid involving 25-hydroxylation, and explains why these patients have an abnormally high cholic acid/ chenodeoxycholic acid ratio in bile (13) .
